Coming soon for patients taking XARELTO® (rivaroxaban): Janssen CarePath for XARELTO® and Janssen Select will transition to XARELTO withMe. We are simplifying access to our patient support in one location with a new name and look. Savings card and coverage gap benefits will not change.
XARELTO® for NONVALVULAR AFIB
A new diagnosis. Starting therapy. All of this can be daunting and overwhelming. But you can be reassured that together, with the right tips, support, and commitment, it's possible to start on the right track. First things first, be sure to fill your XARELTO® (rivaroxaban) prescription if you haven’t yet.
What is XARELTO®?
XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions, no requirements for frequent blood tests, and few drug interactions.
How does XARELTO® work?
XARELTO® slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an enzyme called Factor Xa ("10a").
Reducing stroke risk with XARELTO®
XARELTO® is a prescription medication used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem.
In a clinical trial,
over 96% of people taking XARELTO® remained stroke-free.*
*Rate of first occurrence of stroke was 3.8% for XARELTO® versus 4.3% for warfarin.
Remember, all blood thinners come with a risk of bleeding. A clinical trial comparing XARELTO® to warfarin† for reducing the risk of AFib-related stroke showed that 99% of people taking XARELTO® did not experience a serious bleed. An example of a serious bleed is bleeding into the brain. However, overall major bleeding was similar, and gastrointestinal bleeding was about 1% higher.
†Coumadin® and Jantoven® are brand names for warfarin.